SCHEMBL3246003

SCHEMBL3246003

C[C@]12CCC(=O)C=C1CC[C@H]1[C@@H]3[C@@H]4CC[C@@H]4[C@@](O)(CCC(=O)O)[C@@]3(C)CC[C@@H]12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 7/20 0.57
NR3C1 P04150 6/20 0.57
PGR P06401 5/20 0.57
ALDH1A1 P00352 4/20 0.57
ADRA1A P35348 2/20 0.57
HTR2B P41595 2/20 0.57
LMNA P02545 9/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
SERPINA6 P08185 6/20 0.56
CYP2C19 P33261 4/20 0.56
MAPT P10636 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
BLM P54132 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
MAPK3 P27361 1/20 0.56
SLC6A3 Q01959 1/20 0.56
CYP3A4 P08684 7/20 0.56
HSD17B10 Q99714 6/20 0.56
TSHR P16473 6/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248401 0.93 SMN1; SMN2 (0.57) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10959837 0.92 SMN1; SMN2 (0.56) SHBGNR3C1PGRALDH1A1ADRA1A
Potassium Ion SCHEMBL10786275 0.90 SHBG (0.55) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10783197 0.90 NR3C1 (0.55) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10959339 0.88 PSEN1 (0.58) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL7793950 0.87 SHBG (0.54) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL11508378 0.87 SHBG (0.58) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL3057144 0.87 SHBG (0.58) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL14713210 0.87 SHBG (0.58) SHBGNR3C1PGRALDH1A1ADRA1A
SCHEMBL10781408 0.86 PSEN1 (0.52) SHBGNR3C1PGRALDH1A1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US claimed
EP-1831239-B1 A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA -BISMETHYLENE-17 ALPHA-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID LAMBDA-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS RICHTER GEDEON NYRT (HU) 2010-03-24 EP claimed
US-20080200668-A1 Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-08-21 US claimed
US-20080194812-A1 Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-08-14 US claimed
EP-1817326-A1 INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-08-15 EP claimed
WO-2006059167-A1 INDUSTRIAL PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,16β-BISMETHYLENE-3-OXO-17α-PREGN-4-ENE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-06-08 WO claimed
US-20040242552-A1 New use of antimineralocorticoid compounds against narcotic withdrawal syndrome AVENTIS PHARMA S.A. 2004-12-02 US claimed
EP-0863760-B1 USE OF ANTIMINERALOCORTICOID COMPOUNDS AGAINST DRUG WITHDRAWAL SYNDROME AVENTIS PHARMA SA (FR) 2001-12-05 EP claimed
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US disclosed
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US disclosed
US-8450476-B2 Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements RICHTER GEDEON NYRT. (HU) 2013-05-28 US disclosed
US-8309712-B2 Synthesis of drospirenone in only eight steps; claimed intermediates; readily available raw materials; simple crystallization purification; no hazardous materials; yield RICHTER GEDEON NYRT. (HU) 2012-11-13 US disclosed
US-8309712-B2 Synthesis of drospirenone in only eight steps; claimed intermediates; readily available raw materials; simple crystallization purification; no hazardous materials; yield RICHTER GEDEON NYRT. (HU) 2012-11-13 US disclosed
EP-1817326-B1 INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS RICHTER GEDEON NYRT (HU) 2010-05-19 EP disclosed
EP-1817326-A1 INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegy Szeti Gy R Rt. (HU) 2007-08-15 EP disclosed
WO-2006059167-A1 INDUSTRIAL PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,16β-BISMETHYLENE-3-OXO-17α-PREGN-4-ENE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-06-08 WO disclosed
WO-2006059167-A1 INDUSTRIAL PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,16β-BISMETHYLENE-3-OXO-17α-PREGN-4-ENE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-06-08 WO disclosed
WO-2006059168-A1 A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,l6β-BISMETHYLENE-17α-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-06-08 WO disclosed
US-20040242552-A1 New use of antimineralocorticoid compounds against narcotic withdrawal syndrome AVENTIS PHARMA S.A. 2004-12-02 US disclosed
US-6759399-B1 USING SUCH AS GAMMA-LACTONE OF 10-ETHYNYL-17-HYDROXY-3-OXO-19-NOR-17-PREGNA-4,9(11)-DIENE-21-CARBOXYLIC ACID AVENTIS PHARMA S.A. (FR) 2004-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200668-A1 Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process HSD17B7, CYP17A1, HSD17B11 SHBG 73/4885NR3C1 153/4885PGR 188/4885
US-20080194812-A1 Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process CYP17A1, HSD17B7, HSD17B11 SHBG 57/4885NR3C1 121/4885PGR 132/4885
US-20040242552-A1 New use of antimineralocorticoid compounds against narcotic withdrawal syndrome OPRM1, PNMT, SLC6A11 SHBG 13/4885NR3C1 40/4885PGR 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.